In conclusion, our study underlines, with a real-life approach, that GH/IGF-1 incongruence does not seem to represent a higher risk of metabolic complications, even dyslipidemia, in acromegalic patients, with results aligned with other recent studies. Here, IGF1 is linked to metabolic syndrome.